AbbVie's flagship drug Humira is facing competition from biosimilars, but the company is expected to offset revenue losses in the segment with Skyrizi & Rinvoq. Two real growth drivers for AbbVie are ...

UnitedHealth Group Inc. (NYSE:UNH) reportedly announced on Tuesday that it will remove AbbVie Inc.’s (NYSE:ABBV) blockbuster drug Humira from some of its preferred reimbursement lists starting January ...

Please provide your email address to receive an email when new articles are posted on . CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national ...

As AbbVie Inc. ABBV looks to plug holes in the sales of its mega-blockbuster arthritis drug Humira, newer immunology drugs will be key to the pharmaceutical giant’s future growth, analysts say. When ...

When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. Now, Cigna’s Express Scripts is following suit ...

This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...

CVS also announced that AbbVie and CVS-owned company Cordavis, which launched in August, will produce a co-branded version of Humira that will be made available to customers in the second quarter of ...

The biggest U.S. drug benefits manager is making a move that will take a bite out of sales for the world’s top-selling medication. CVS Health Corp. will remove AbbVie’s Humira from most of its lists ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Oct 20 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a head-to-head . AbbVie has been ...